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The aim of this study is to develop an innovative and alternative nucleic acid-based
method for multidrug-resistant tuberculosis (MDR-TB) and extensively drug resistant
tuberculosis (XDR-TB) diagnostics, such as the Cepheid GeneXPert or the Hain–Line Probe
Assay methods, to simultaneously identify MDR-TB (patient benefit) and to provide clues
as to MDR-TB transmission (community benefit) at a reasonable cost to the national public
health programs.
The DPO (Dual-Priming Oligonucleotide) principle was used to initially develop a 4-Plex
multiplexed polymerase chain reaction (PCR) that simultaneously amplifies: (1) the CRISPR;
(2) the rpoB hotspot, the katG and the inhA genes. The current maximal version of the assay
allows the characterization of up to 68 markers, 59 of which are used routinely in one step
(for the Luminex 200) or two-step methods (for the MagPix). Spoligotyping requires 43
markers, and rpoB516, 526, 531, katG315, inhA-8, -15, gyrA94, rrs1401, 1402, 1484 requires
25 markers. For each primer couple, one is biotinylated. Hybridization is performed after
a PCR reaction on a microbead-based suspension array device with individually detectable
oligonucleotide-coupled beads (Luminex 200 or MagPix systems) and detection proceeds
through Streptavidin–Phycoerythrin labelling of the biotinylated-hybridized PCR products.
This study shows that this technique provides 100% specificity and sensitivity for rpoB
and 100% specificity and 90% sensitivity for isoniazid resistance on DNA extracted from
cultures, compared with phenotypic DST. The method was fully validated against sequenc-
ing. The method is currently in the experimental validation phase on DNA extracted from
biological material and preliminary results will be shown. This technique was recently
upgraded to detect fluoroquinolone and aminoglycoside resistance by including 2 new
PCR primer couples and 9 more probes on the rrs and gyrA genes. It is suggested that
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to perform national TB-resistance surveys and would also allow to delineate more pre-
cisely, without further enquiries, MDR-TB transmission risks.
In conclusion, these methods appear to be both economically and technically very inno-
vative. The extension from a Research Use Only to a CE-marked In-Vitro Diagnostics assay
is in progress.
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